Biostealth technology for conventionally cross-linked biologic medical devices​

Facta® is developed for biologic medical devices treated with conventional cross-linking and fixation methods.

Designed to preserve the structural and functional properties of bioprosthetic devices, Facta is engineered to inhibit immune-related responses. As a consequence, this reduces calcification, inflammation, and tissue degeneration over time.

Facta is designed to support long-term tissue durability and reliability across a broad range of biologic medical devices.

Plant-based ingredients

Applications

Cardiovascular devices
  • Percutaneous valves
  • Surgical valves
  • Biologic tissue patches
  • Tendons and ligaments
  • Bones
  • Biomaterials (matrices, fibers)
  • Vascular patches
  • Dialysis fistulae
  • Others
  • Vaginal reconstruction
  • Breast reconstruction
  • Intervertebral discs
  • Dura mater
  • Bioartificial nerves
  • Others

Benefits of Facta

Facta is designed to support biologic devices treated with conventional cross-linking.

How Facta Works

Facta creates a stable bridge between biologic tissue and aldehyde-based fixatives, forming a protective 3D network designed to stabilize biomaterials and limit tissue degeneration over time.
 

By permanently capping free aldehyde groups, Facta helps reduce the risk of calcification.

Protection against the chief reasons for device failure and limited duration

Facta’s Key Advantages

1.

Prevents circulating antibodies from interacting with antigens on and inside the tissue

2.

Inhibits pathogenic microorganisms from binding and colonizing the substrate

3.

Avoids the precipitation of calcium and activation of the coagulation cascade, preventing blood clot formation

Learn more about BCI technology designed to enhance the biocompatibility of medical devices